Pulmonary vascular disease & thromboembolism
Association of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: The TRAVERSE trial
Authors' conclusion
TRT increased circulating neutrophils and monocytes and decreased lymphocytes and platelets in men with hypogonadism. Changes in monocyte and neutrophil counts were associated with increased risk of VTE.
Study context
- Population
- Men 45–80 years with hypogonadism and preexisting or increased risk of cardiovascular disease (CVD)
- Participants
- 5,204 men
- Comparison
- Transdermal testosterone vs placebo gel
- Primary endpoint
- Effect of TRT on neutrophils, monocytes, lymphocytes and platelets; association of changes with MACE and venous thromboembolism (VTE)
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
- Testosterone replacement therapy (TRT): significantly greater increase in neutrophils and monocytes, greater decrease in lymphocytes and platelets vs placebo
Further findings
| Outcome | OR (CI) | |
|---|---|---|
| MACE, by neutrophil and monocyte counts (OR per 1 SD increase)Adjusted for treatment | 1.25 (1.12–1.40) | |
| 0.512Odds ratio (log scale) |
Change in leukocyte subsets and platelets
- TRT: significantly greater increase in neutrophils and monocytes and greater decrease in lymphocytes and platelets than placebo
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: The TRAVERSE trial. Am Heart J. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →